|
Press Releases |
|
 |
|
Tuesday, June 7, 2022 |
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
Friday, May 13, 2022 |
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
Thursday, March 17, 2022 |
|
Hua Medicine Announces 2021 Annual Results |
Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
Sunday, September 26, 2021 |
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
Wednesday, September 15, 2021 |
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
Thursday, August 19, 2021 |
|
Hua Medicine Announces 2021 Interim Results |
Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
Friday, April 23, 2021 |
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
Friday, March 19, 2021 |
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
Friday, December 18, 2020 |
|
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial |
Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: more info >> |
|
Wednesday, October 14, 2020 |
|
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin |
Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
New Report Reveals Key Considerations For Successful Distribution Onboarding
Jul 31, 2025 16:48 HKT/SGT
|
|
|
Over 20 Million Shares Repurchased in Two Days, Shoucheng Holdings Sends a Strong Signal with Decisive Action
Jul 31, 2025 16:43 HKT/SGT
|
|
|
Shoucheng Buys Back 20M Shares in 2 Days, Signals Strong Bet
Jul 31, 2025 16:40 HKT/SGT
|
|
|
Champion REIT Hosts ESG-Themed Event for a Third Year, Redefining Value and Sustainable Future of Commercial Properties Through Innovation
Jul 31, 2025 16:40 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL GROUP Announces Business Partnership with JEPLAN to Realize a Decarbonized, Circular Society
Jul 31, 2025 15:00 JST
|
|
|
Wintermar Offshore (WINS:JK) Reports 1H2025 Results
Jul 31, 2025 10:56 HKT/SGT
|
|
|
DENSO Announces First Quarter Financial Results
Jul 31, 2025 11:25 JST
|
|
|
Honda Launches All-New Prelude Teaser Page Ahead of Scheduled September 2025 Market Introduction
Jul 31, 2025 11:20 JST
|
|
|
MHI Demonstrates Transport of Relief Supplies in the Event of a Disaster Using Uncrewed Aerial Vehicles Currently in Development
Jul 31, 2025 11:00 JST
|
|
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Jul 31, 2025 9:30 JST
|
|
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
Jul 31, 2025 9:20 JST
|
|
|
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Jul 31, 2025 9:10 JST
|
|
|
HKTDC welcomes the 'Report on Hong Kong's Business Environment' and continues to actively promote Hong Kong's advantages
Jul 30, 2025 22:40 HKT/SGT
|
|
|
Hong Kong Shopping Festival Returns in August with Bigger and Better 2nd Edition
Jul 30, 2025 22:40 HKT/SGT
|
|
|
Naoris Protocol Announces Upcoming TGE for $NAORIS
Jul 30, 2025 22:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|